Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LILLY-FUNDED MEDSTAT SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM TO BUILD DISEASE MANAGEMENT DATABASE; ZYPREXA/RISPERDAL STUDY TO CONCLUDE BY DECEMBER

Executive Summary

Medstat is conducting a multi-site, observational study of 2,400 schizophrenia patients with funding from Lilly to examine quality of life and outcomes in routine schizophrenia care. The Schizophrenia Care and Assessment Program was initiated a year and half ago as part of Lilly's focus on "disease prevention and management in the area of schizophrenia," Medstat Outcomes and Clinical Research Manager Kim Heithoff told an Institute for International Research conference in Philadelphia Sept. 27.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel